Ripple-backed Evernorth’s $1B deal targets world’s largest XRP treasury!

ambcryptoPublished on 2025-10-20Last updated on 2025-10-21

Key Takeaways

How much funding will the deal generate?

The transaction is expected to raise over $1 billion in gross proceeds, including $200 million from SBI and other investments from Ripple.

When is the deal expected to close?

The merger is expected to close in the first quarter of 2026.


Evernorth Holdings Inc., a newly formed company based in Nevada, has officially launched operations.

 Its primary goal is to promote large-scale institutional adoption of Ripple [XRP], signaling a bold and ambitious strategy in the crypto space.

Evernorth and Armada merger

Evernorth Holdings Inc. has announced a merger agreement with Armada Acquisition Corp., a publicly traded special purpose acquisition company (SPAC).

Once the deal closes, the combined company will operate under the Evernorth name and trade on Nasdaq under the ticker symbol “XRPN.”  The merger will raise over $1 billion in gross proceeds.

This includes a $200 million investment from SBI. In addition, Evernorth has secured support from major crypto and finance players. These include Ripple, Rippleworks, Pantera Capital, Kraken, GSR, and Ripple co-founder Chris Larsen. 

As a next step, Evernorth will use much of the capital to buy XRP on the open market. The goal is to build the world’s largest institutional XRP treasury.

 It will allocate the remaining funds to support its operational and corporate initiatives.

Remarking on the same, Asheesh Birla, CEO of Evernorth, said, 

“Evernorth is built to provide investors more than just exposure to XRP’s price. As we capitalize on existing TradFi yield generation strategies and deploy into DeFi yield opportunities, we also contribute to the growth and maturity of that ecosystem.”

Evernorth and Armada plan to complete their merger in the first quarter of 2026, aiming to create the largest publicly traded XRP treasury company to date.

XRP conversation surges

The announcement sparked strong market and social media activity. According to LunarCrush, XRP-related discussions surged after the $1 billion fundraising news. 

As a result, mentions and engagement peaked while the treasury story gained momentum, pushing XRP’s AltRank to 790 and Galaxy Score to 72. These scores reflect rising sentiment, supported by steady interaction quality and active price movement.

Praising XRP’s success and demand, Brad Garlinghouse, CEO of Ripple, added, 

“Ripple has long championed XRP for its utility as a global asset for the efficient settlement of payments around the world.”

XRP price action and whale activity

This coincided with XRP’s recent market performance, reflecting a complex blend of short-term volatility and long-term optimism.

While XRP slipped 0.6% over the past 24 hours and 4.15% over the week and was trading at $2.43, at press time, Santiment data shows that wallets holding over 10,000 XRP have reached a record high of roughly 317,500. 

This further concided with Ripple making a major push into the Digital Asset Treasury space with a $1B SPAC to accumulate XRP and a $1B acquisition of GTreasury.

Together, all these moves are redefining XRP’s role within global finance, shifting its narrative from speculative asset to a cornerstone of institutional liquidity.

Share

Related Reads

JPMorgan Research Report Analysis: Moderna's INT Trial Meets Endpoints, but Market Already Priced In

On August 19, J.P. Morgan (JPM) published a research report analyzing Moderna's recent Phase III trial success for its Individualized Neoantigen Therapy (INT), developed in partnership with Merck, in adjuvant melanoma. The trial met its primary endpoint of significantly improved recurrence-free survival and the key secondary endpoint of distant metastasis-free survival. While JPM acknowledged the strong clinical value of these results, particularly the prevention of distant metastasis, the bank stated that this success was widely anticipated, with an 85% prior probability of success, and is already reflected in Moderna's current market valuation. Following the announcement, Moderna's stock rose in pre-market trading. However, JPM maintained its Underweight rating and $40 price target, implying approximately 36% downside from the current price of ~$63. The core rationale is that the success in adjuvant melanoma, a relatively small market in immuno-oncology, is fully priced in. Moderna's future valuation hinges entirely on INT's ability to demonstrate similar efficacy across broader cancer indications. JPM's valuation model incorporates only a modest risk-adjusted value (~$3/share) for the melanoma approval. Approximately $15/share of its target price is attributed to INT's potential in other cancer types. The report identifies upcoming data readouts in non-melanoma cancers (e.g., lung, head & neck, renal) as the critical variable that will determine the platform's ultimate value. Upside risks include better-than-expected data in these new indications, while downside risks involve clinical failures, regulatory delays, or commercial underperformance. In conclusion, JPM views the pre-market stock move as driven by short covering and trading sentiment rather than a fundamental re-rating. The bank remains bearish, arguing that Moderna must now prove INT's efficacy as a platform technology beyond melanoma to justify its current market cap.

marsbit8m ago

JPMorgan Research Report Analysis: Moderna's INT Trial Meets Endpoints, but Market Already Priced In

marsbit8m ago

Treasury Department Directly Intervenes to Suppress Long-Term Interest Rates

The article discusses the U.S. Treasury's recent direct intervention to suppress long-term bond yields through buyback operations. While distinct from traditional Yield Curve Control (YCC), this move is interpreted as direct government intervention in its own financing costs. The author emphasizes the short-term tactical nature of this action and contrasts it with the Federal Reserve's upcoming, potentially divergent, policy stance at Jackson Hole. The core issue is framed as a long-term U.S. strategic dilemma: managing high deficit levels. The analysis argues that deficit reduction cannot realistically come from spending cuts or traditional industries, but must rely on achieving higher economic growth driven by technological breakthroughs. Current monetary tightening, while possibly curbing yields and inflation in the short term, is seen as potentially counterproductive to this necessary long-term investment in technology and supply chain resilience. The piece draws historical parallels, placing the current intervention between the 2000-2002 Treasury buybacks (for liquidity) and larger-scale Fed-led "Operation Twist" maneuvers. The effectiveness of the Treasury's action is deemed limited without Federal Reserve cooperation, which would signify a more significant policy shift. Ultimately, the author views such technical, bureaucratic interventions as treating symptoms rather than the underlying disease of the U.S. economy's structural challenges and "K-shaped" divergence. The conclusion suggests that sustained yield suppression by the Fed, combined with specific geopolitical outcomes, could serve as a catalyst for a more profound discussion on broader U.S. and dollar trajectory.

marsbit8m ago

Treasury Department Directly Intervenes to Suppress Long-Term Interest Rates

marsbit8m ago

Trading

Spot
活动图片